Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
Abstract
:1. Introduction
2. Pathogenesis of HCC Development after DAA Therapy
3. Time Association between DAA Treatment and HCC Recurrence
4. Presenting Non-Characterized Nodules before DAA Treatment and the Risk of Developing HCC
5. Serum Markers as Predictors of HCC Development
6. Impact of HCC Recurrence on the Overall Survival of Patients Treated with DAA
7. The Minimum Information That the Studies Need to Report in Order to Disregard the Alarm
8. Conclusions
Author Contributions
Acknowledgments
Conflicts of Interest
References
- Blach, S.; Zeuzem, S.; Manns, M.; Altraif, I.; Duberg, A.-S.; Muljono, D.H.; Waked, I.; Alavian, S.M.; Lee, M.-H.; Negro, F.; et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol. 2017, 2, 161–176. [Google Scholar] [CrossRef]
- Pubmed Search: Hepatocellular Carcinoma and Direct Antiviral Agents. Available online: https://www.ncbi.nlm.nih.gov/pubmed/?term=hepatocellular+carcinoma+and+direct+antiviral+agents (accessed on 28 January 2019).
- Colombo, M.; Boccaccio, V. HCV therapy and risk of liver cancer recurrence: who to treat? Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 392–393. [Google Scholar] [CrossRef] [PubMed]
- Guarino, M.; Viganò, L.; Ponziani, F.R.; Giannini, E.G.; Lai, Q.; Morisco, F.; Vitale, A.; Russo, F.P.; Cillo, U.; Burra, P.; et al. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Dig. Liver Dis. 2018, 50, 1105–1114. [Google Scholar] [CrossRef] [PubMed]
- Saraiya, N.; Yopp, A.C.; Rich, N.E.; Odewole, M.; Parikh, N.D.; Singal, A.G. Systematic review with meta-analysis: Recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment. Pharmacol. Ther. 2018, 48, 127–137. [Google Scholar] [CrossRef] [PubMed]
- Reig, M.; Boix, L.; Bruix, J. The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. Liver Int. 2017, 37, 136–139. [Google Scholar] [CrossRef] [PubMed]
- Baumert, T.F.; Jühling, F.; Ono, A.; Hoshida, Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med. 2017, 15, 52. [Google Scholar] [CrossRef] [PubMed]
- Piscaglia, F.; Granito, A.; Bolondi, L. DAAs for HCV and risk of hepatocellular carcinoma: Current standpoint. Lancet Gastroenterol. Hepatol. 2018, 3, 736–738. [Google Scholar] [CrossRef]
- Tampaki, M.; Savvanis, S.; Koskinas, J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: Evidence and pathophysiological issues. Ann. Gastroenterol. 2018, 31, 670–679. [Google Scholar] [CrossRef]
- Pawlotsky, J.-M. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 2016, 151, 70–86. [Google Scholar] [CrossRef] [PubMed]
- Lin, M.V.; King, L.Y.; Chung, R.T. Hepatitis C Virus–Associated Cancer. Annu. Rev. Pathol. Mech. Dis. 2015, 10, 345–370. [Google Scholar] [CrossRef] [PubMed]
- Sarasin-Filipowicz, M.; Oakeley, E.J.; Duong, F.H.T.; Christen, V.; Terracciano, L.; Filipowicz, W.; Heim, M.H. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 2008, 105, 7034–7039. [Google Scholar] [CrossRef] [Green Version]
- Meissner, E.G.; Wu, D.; Osinusi, A.; Bon, D.; Virtaneva, K.; Sturdevant, D.; Porcella, S.; Wang, H.; Herrmann, E.; McHutchison, J.; et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J. Clin. Investig. 2014, 124, 3352–3363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rehermann, B. Natural Killer Cells in Viral Hepatitis. Cell. Mol. Gastroenterol. Hepatol. 2015, 1, 578–588. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Serti, E.; Chepa-Lotrea, X.; Kim, Y.J.; Keane, M.; Fryzek, N.; Liang, T.J.; Ghany, M.; Rehermann, B. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology 2015, 149, 190–200e2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chu, P.-S.; Nakamoto, N.; Taniki, N.; Ojiro, K.; Amiya, T.; Makita, Y.; Murata, H.; Yamaguchi, A.; Shiba, S.; Miyake, R.; et al. On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. PLoS ONE 2017, 12, e0179096. [Google Scholar] [CrossRef] [PubMed]
- Pahl, J.; Cerwenka, A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology 2017, 222, 11–20. [Google Scholar] [CrossRef] [PubMed]
- Rehermann, B. Pathogenesis of chronic viral hepatitis: Differential roles of T cells and NK cells. Nat. Med. 2013, 19, 859–868. [Google Scholar] [CrossRef] [PubMed]
- van Wilgenburg, B.; Scherwitzl, I.; Hutchinson, E.C.; Leng, T.; Kurioka, A.; Kulicke, C.; de Lara, C.; Cole, S.; Vasanawathana, S.; Limpitikul, W.; et al. MAIT cells are activated during human viral infections. Nat. Commun. 2016, 7, 11653. [Google Scholar] [CrossRef] [Green Version]
- Burchill, M.A.; Golden-Mason, L.; Wind-Rotolo, M.; Rosen, H.R. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals. J. Viral Hepat. 2015, 22, 983–991. [Google Scholar] [CrossRef]
- Martin, B.; Hennecke, N.; Lohmann, V.; Kayser, A.; Neumann-Haefelin, C.; Kukolj, G.; Böcher, W.-O.; Thimme, R. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J. Hepatol. 2014, 61, 538–543. [Google Scholar] [CrossRef] [PubMed]
- Hengst, J.; Strunz, B.; Deterding, K.; Ljunggren, H.-G.; Leeansyah, E.; Manns, M.P.; Cornberg, M.; Sandberg, J.K.; Wedemeyer, H.; Björkström, N.K. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur. J. Immunol. 2016, 46, 2204–2210. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teng, M.W.L.; Swann, J.B.; Koebel, C.M.; Schreiber, R.D.; Smyth, M.J. Immune-mediated dormancy: An equilibrium with cancer. J. Leukoc. Biol. 2008, 84, 988–993. [Google Scholar] [CrossRef]
- Naumov, G.N.; MacDonald, I.C.; Weinmeister, P.M.; Kerkvliet, N.; Nadkarni, K.V.; Wilson, S.M.; Morris, V.L.; Groom, A.C.; Chambers, A.F. Persistence of solitary mammary carcinoma cells in a secondary site: A possible contributor to dormancy. Cancer Res. 2002, 62, 2162–2168. [Google Scholar] [PubMed]
- Schmidt-Kittler, O.; Ragg, T.; Daskalakis, A.; Granzow, M.; Ahr, A.; Blankenstein, T.J.F.; Kaufmann, M.; Diebold, J.; Arnholdt, H.; Muller, P.; et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc. Natl. Acad. Sci. 2003, 100, 7737–7742. [Google Scholar] [CrossRef] [Green Version]
- Weckermann, D.; Polzer, B.; Ragg, T.; Blana, A.; Schlimok, G.; Arnholdt, H.; Bertz, S.; Harzmann, R.; Klein, C.A. Perioperative Activation of Disseminated Tumor Cells in Bone Marrow of Patients with Prostate Cancer. J. Clin. Oncol. 2009, 27, 1549–1556. [Google Scholar] [CrossRef]
- Ehrlich P Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 1909, 5, 273–290.
- Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991–998. [Google Scholar] [CrossRef]
- Collins, J.M.; Raphael, K.L.; Terry, C.; Cartwright, E.J.; Pillai, A.; Anania, F.A.; Farley, M.M. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin. Infect. Dis. 2015, 61, 1304–1306. [Google Scholar] [CrossRef] [PubMed]
- Perelló, M.C.; Fernández-Carrillo, C.; Londoño, M.-C.; Arias-Loste, T.; Hernández-Conde, M.; Llerena, S.; Crespo, J.; Forns, X.; Calleja, J.L. Reactivation of Herpesvirus in Patients With Hepatitis C Treated with Direct-Acting Antiviral Agents. Clin. Gastroenterol. Hepatol. 2016, 14, 1662–1666. [Google Scholar] [CrossRef] [PubMed]
- Bassendine, M.F.; Sheridan, D.A.; Bridge, S.H.; Felmlee, D.J.; Neely, R.D.G. Lipids and HCV. Semin. Immunopathol. 2013, 35, 87–100. [Google Scholar] [CrossRef]
- Moucari, R.; Asselah, T.; Cazals–Hatem, D.; Voitot, H.; Boyer, N.; Ripault, M.; Sobesky, R.; Martinot–Peignoux, M.; Maylin, S.; Nicolas–Chanoine, M.; et al. Insulin Resistance in Chronic Hepatitis C: Association with Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis. Gastroenterology 2008, 134, 416–423. [Google Scholar] [CrossRef] [PubMed]
- Luna, J.M.; Scheel, T.K.H.; Danino, T.; Shaw, K.S.; Mele, A.; Fak, J.J.; Nishiuchi, E.; Takacs, C.N.; Catanese, M.T.; de Jong, Y.P.; et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell 2015, 160, 1099–1110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hsu, S.; Wang, B.; Kota, J.; Yu, J.; Costinean, S.; Kutay, H.; Yu, L.; Bai, S.; La Perle, K.; Chivukula, R.R.; et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Investig. 2012, 122, 2871–2883. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Milner, K.-L.; Jenkins, A.B.; Trenell, M.; Tid-Ang, J.; Samocha-Bonet, D.; Weltman, M.; Xu, A.; George, J.; Chisholm, D.J. Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. J. Viral Hepat. 2014, 21, 325–332. [Google Scholar] [CrossRef] [PubMed]
- Gitto, S.; Cicero, A.F.G.; Loggi, E.; Giovannini, M.; Conti, F.; Grandini, E.; Guarneri, V.; Scuteri, A.; Vitale, G.; Cursaro, C.; et al. Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. Ann. Hepatol. 2017, 17, 64–75. [Google Scholar] [CrossRef]
- Halley-Stott, R.P.; Gurdon, J.B. Epigenetic memory in the context of nuclear reprogramming and cancer. Brief. Funct. Genom. 2013, 12, 164–173. [Google Scholar] [CrossRef] [Green Version]
- Ono, A.; Goossens, N.; Finn, R.S.; Schmidt, W.N.; Thung, S.N.; Im, G.Y.; Hoshida, Y. Precision Liver Cancer Prevention Consortium Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. Hepatology 2017, 66, 1344–1346. [Google Scholar] [CrossRef] [PubMed]
- Nakagawa, S.; Wei, L.; Song, W.M.; Higashi, T.; Ghoshal, S.; Kim, R.S.; Bian, C.B.; Yamada, S.; Sun, X.; Venkatesh, A.; et al. Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell 2016, 30, 879–890. [Google Scholar] [CrossRef] [PubMed]
- Reig, M.; Mariño, Z.; Perelló, C.; Iñarrairaegui, M.; Ribeiro, A.; Lens, S.; Díaz, A.; Vilana, R.; Darnell, A.; Varela, M.; et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 2016, 65, 719–726. [Google Scholar] [CrossRef]
- Conti, F.; Buonfiglioli, F.; Scuteri, A.; Crespi, C.; Bolondi, L.; Caraceni, P.; Foschi, F.G.; Lenzi, M.; Mazzella, G.; Verucchi, G.; et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J. Hepatol. 2016, 65, 727–733. [Google Scholar] [CrossRef] [PubMed]
- Renzulli, M.; Buonfiglioli, F.; Conti, F.; Brocchi, S.; Serio, I.; Foschi, F.G.; Caraceni, P.; Mazzella, G.; Verucchi, G.; Golfieri, R.; et al. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur. Radiol. 2018, 28, 506–513. [Google Scholar] [CrossRef] [PubMed]
- ANRS collaborative Study Group on Hepatocellular Carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J. Hepatol. 2016, 65, 734–740. [Google Scholar] [CrossRef] [PubMed]
- Ikeda, K.; Kawamura, Y.; Kobayashi, M.; Kominami, Y.; Fujiyama, S.; Sezaki, H.; Hosaka, T.; Akuta, N.; Saitoh, S.; Suzuki, F.; et al. Direct-Acting Antivirals Decreased Tumor Recurrence after Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig. Dis. Sci. 2017, 62, 2932–2942. [Google Scholar] [CrossRef] [PubMed]
- Cabibbo, G.; Petta, S.; Calvaruso, V.; Cacciola, I.; Cannavò, M.R.; Madonia, S.; Distefano, M.; Larocca, L.; Prestileo, T.; Tinè, F.; et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment. Pharmacol. Ther. 2017, 46, 688–695. [Google Scholar] [CrossRef] [PubMed]
- Beste, L.A.; Green, P.K.; Berry, K.; Kogut, M.J.; Allison, S.K.; Ioannou, G.N. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J. Hepatol. 2017, 67, 32–39. [Google Scholar] [CrossRef] [PubMed]
- Prenner, S.B.; VanWagner, L.B.; Flamm, S.L.; Salem, R.; Lewandowski, R.J.; Kulik, L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J. Hepatol. 2017, 66, 1173–1181. [Google Scholar] [CrossRef] [PubMed]
- Saberi, B.; Dadabhai, A.S.; Durand, C.M.; Philosophe, B.; Cameron, A.M.; Sulkowski, M.S.; Gurakar, A. Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma. Hepatology 2017, 66, 661–663. [Google Scholar] [CrossRef] [PubMed]
- Adhoute, X.; Penaranda, G.; Raoul, J.L.; Sellier, F.; Castellani, P.; Oules, V.; Perrier, H.; Lefolgoc, G.; Pol, B.; Campanile, M.; et al. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur. J. Gastroenterol. Hepatol. 2018, 30, 368–375. [Google Scholar] [CrossRef]
- Abdelaziz, A.O.; Nabil, M.M.; Abdelmaksoud, A.H.; Shousha, H.I.; Cordie, A.A.; Hassan, E.M.; Omran, D.A.; Leithy, R.; Elbaz, T.M. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus. Eur. J. Gastroenterol. Hepatol. 2018, 30, 39–43. [Google Scholar] [CrossRef]
- El Kassas, M.; Funk, A.L.; Salaheldin, M.; Shimakawa, Y.; Eltabbakh, M.; Jean, K.; El Tahan, A.; Sweedy, A.T.; Afify, S.; Youssef, N.F.; et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis. J. Viral Hepat. 2018, 25, 623–630. [Google Scholar] [CrossRef] [PubMed]
- Sugiura, A.; Joshita, S.; Umemura, T.; Yamazaki, T.; Fujimori, N.; Kimura, T.; Matsumoto, A.; Igarashi, K.; Usami, Y.; Wada, S.; et al. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J. Viral Hepat. 2018, 25, 1462–1471. [Google Scholar] [CrossRef]
- Lleo, A.; Aglitti, A.; Aghemo, A.; Maisonneuve, P.; Bruno, S.; Persico, M.; Rendina, M.; Ciancio, A.; Lampertico, P.; Brunetto, M.R.; et al. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig. Liver Dis. 2019, 51, 310–317. [Google Scholar] [CrossRef]
- Hassany, M.; Elsharkawy, A.; Maged, A.; Mehrez, M.; Asem, N.; Gomaa, A.; Mostafa, Z.; Abbas, B.; Soliman, M.; Esmat, G. Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact. Eur. J. Gastroenterol. Hepatol. 2018, 30, 876–881. [Google Scholar] [CrossRef] [PubMed]
- Hernáez-Alsina, T.B.; Caballol-Oliva, B.; Díaz-González, A.; Guedes-Leal, C.; Reig, M. Risk of recurrence of Hepatocellular Carcinoma in patients treated with interferon-free antivirals. Gastroenterol. Hepatol. 2019. (In press) [Google Scholar]
- Ogawa, E.; Furusyo, N.; Nomura, H.; Dohmen, K.; Higashi, N.; Takahashi, K.; Kawano, A.; Azuma, K.; Satoh, T.; Nakamuta, M.; et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment. Pharmacol. Ther. 2018, 47, 104–113. [Google Scholar] [CrossRef]
- Forner, A.; Reig, M.; Bruix, J. Hepatocellular carcinoma. Lancet 2018, 391, 1301–1314. [Google Scholar] [CrossRef]
- Allaire, M.; Rekik, S.; Layese, R.; Mumana, A.; Guyot, E.; Nkontchou, G.; Bourcier, V.; Grando, V.; Ziol, M.; Nahon, P.; et al. Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis. Dig. Liver Dis. 2019, 51, 86–94. [Google Scholar] [CrossRef] [PubMed]
- Mariño, Z.; Darnell, A.; Lens, S.; Sapena, V.; Díaz, A.; Belmonte, E.; Perelló, C.; Calleja, J.L.; Varela, M.; Rodriguez, M.; et al. Time association between HCV therapy and hepatocellular carcinoma emergence in patients with cirrhosis. The relevance of non-characterized nodules. J. Hepatol. 2019, 70, 874–884. [Google Scholar] [CrossRef]
- Nahon, P.; Layese, R.; Bourcier, V.; Cagnot, C.; Marcellin, P.; Guyader, D.; Pol, S.; Larrey, D.; De Lédinghen, V.; Ouzan, D.; et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018, 155, 1436–1450. [Google Scholar] [CrossRef]
- Tripodi, A.; D’Ambrosio, R.; Padovan, L.; Tosetti, G.; Aghemo, A.; Primignani, M.; Chantarangkul, V.; Peyvandi, F.; Colombo, M. Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver Int. 2017, 37, 1295–1303. [Google Scholar] [CrossRef] [PubMed]
- Villani, R.; Vendemiale, G.; Serviddio, G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int. J. Mol. Sci. 2018, 20, 49. [Google Scholar] [CrossRef] [PubMed]
- Orr, C.; Aartun, J.; Masur, H.; Kottilil, S.; Meissner, E.G. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J. Viral Hepat. 2019, 26, 323–328. [Google Scholar] [CrossRef]
- Faillaci, F.; Marzi, L.; Critelli, R.; Milosa, F.; Schepis, F.; Turola, E.; Andreani, S.; Vandelli, G.; Bernabucci, V.; Lei, B.; et al. Liver Angiopoietin-2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer after Hepatitis CVirus Direct-Acting Antivirals. Hepatology 2018, 68, 1010–1024. [Google Scholar] [CrossRef] [PubMed]
- Mashiba, T.; Joko, K.; Kurosaki, M.; Ochi, H.; Osaki, Y.; Kojima, Y.; Nakata, R.; Goto, T.; Takehiro, A.; Kimura, H.; et al. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS ONE 2018, 13, e0194704. [Google Scholar] [CrossRef]
- Cabibbo, G.; Petta, S.; Barbara, M.; Attardo, S.; Bucci, L.; Farinati, F.; Giannini, E.G.; Negrini, G.; Ciccarese, F.; Rapaccini, G.L.; et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J. Hepatol. 2017, 67, 65–71. [Google Scholar] [CrossRef] [PubMed]
- Reig, M.; Boix, L.; Mariño, Z.; Torres, F.; Forns, X.; Bruix, J. Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure? Semin. Liver Dis. 2017, 37, 109–118. [Google Scholar] [Green Version]
- Cabibbo, G.; Petta, S.; Barbàra, M.; Missale, G.; Virdone, R.; Caturelli, E.; Piscaglia, F.; Morisco, F.; Colecchia, A.; Farinati, F.; et al. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int. 2017, 37, 1157–1166. [Google Scholar] [CrossRef]
Authors, Year | Journal | Type of Publication | Type of Study | N | SVR (%) | ||
---|---|---|---|---|---|---|---|
ACTIVE HCC | HCC CR | No HCC | |||||
Reig M, 2016 | J Hepatol | Original | Retrospective | 58 (HCC CR) | -- | 97.5 | -- |
Conti F, 2016 * | J Hepatol | Original | Retrospective | 59 (HCC CR) 285 (No HCC) | -- | 89.8 | 91.6 |
The ANRS collaborative study group on HCC, 2016 | J Hepatol | Original | Prospective | 189 (HCC CR) 1 13 (HCC CR) 2 | -- | 91.91 1002 | -- |
Ikeda K, 2017 | Dig Dis Sci | Original | Retrospective | 177 (HCC CR) | -- | 89.6 | -- |
Cabibbo G, 2017 | Aliment Pharmacol Ther | Original | Prospective | 143 (HCC CR) | -- | 96 | -- |
Beste LA, 2017 | J Hepatol | Original | Retrospective | 482 (Active HCC) 17 (No HCC) | 74 | -- | 91.1 |
Prenner SB, 2017 | J Hepatol | Original | Retrospective | 59 (Active HCC) 76 (HCC CR) 284 (No HCC) | 57 | 97 | 88 |
Saberi B, 2017 | Hepatology | Original | Retrospective | 21 (Active HCC) | 67 | -- | - |
Adhoute X, 2018 | Eur J Gastr Hepatol | Original | Retrospective | 22 (HCC CR) | -- | 86 | -- |
Hassany M, 2018 | Eur J Gastr Hepatol | Original | Prospective | 62 (HCC CR) | -- | 64.5 | -- |
El Kassas M, 2018 | J Viral Hepat | Original | Prospective | 53 (HCC CR) | -- | 77.4 | -- |
Abdelaziz AO, 2018 | Eur J Gastr Hepatol | Original | Retrospective | 45 (HCC CR) 44 (No HCC) | -- | 64.4 | 70.5 |
Sugiura A, 2018 | J Viral Hepat | Original | Prospective | 79 (HCC CR) 759 (No HCC) | -- | 87.3 | 95.5 |
Leo A, 2018 | Dig Liver Dis | Original | Prospective | 161 (HCC CR) 1766 (No HCC) | -- | 95 | 95.1 |
Author | Reig et al. | Conti el al./Renzulli et al. | Cabibbo et al. | Cabibbo et al. |
---|---|---|---|---|
Publication | Journal of Hepatology 2016 | Journal of Hepatology 2016 | Aliment Pharmacology Therapy 2017 | Journal of Hepatology 2017 |
Seminar Liver Disease 2017 | European radiology 2017 | |||
Type of study | Retrospective | Prospective | Retrospective | |
HCC treatment | RFA/PEI/ Resection/TACE | RFA/PEI/ Resection | ||
BCLC 0/A (%) | 97.4 | 98.3 | 100 | 100 |
HCC status before DAA initiation | CR | 3 patients without CR | CR | CR |
without non-characterized nodules | without non-characterized nodules | |||
HCV-status | All | no-SVR | ||
n | 77 | 59 | 143 | 328 |
Follow-up | At least one radiological assessment | |||
Median Follow-up (months) | 12.4 (IQR: 8.4–18.7) | 12.4 (range 1.5–90.2) | 8.7 months (range 3–19) | 27 (range 3–95) |
HCC recurrence % | 31.2% | 30.5% | 20.3% | 43.3% |
6-months | NA | 12% | ||
12-months | 26.6% | 21% | ||
18-months | 29.1% | |||
24-months | 41% | |||
Death (%) | 6.5% | NA | 4.2% | 1st year-3% |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sanduzzi-Zamparelli, M.; Boix, L.; Leal, C.; Reig, M. Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. Viruses 2019, 11, 406. https://doi.org/10.3390/v11050406
Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M. Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. Viruses. 2019; 11(5):406. https://doi.org/10.3390/v11050406
Chicago/Turabian StyleSanduzzi-Zamparelli, Marco, Loreto Boix, Cassia Leal, and María Reig. 2019. "Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents" Viruses 11, no. 5: 406. https://doi.org/10.3390/v11050406